American College of Obstetrics and Gynecologists (ACOG) annual meeting. Investor focus will be on Columbia Labs ( CBRX) and KV Pharmaceutical ( KV-A). May 2:
Dendreon ( DNDN) first-quarter earnings. May 3:
Vertex Pharmaceuticals ( VRTX) first-quarter earnings.
Mannkind ( MNKD) presents at the Deutsche Bank healthcare investor conference.
Alimera Sciences ( ALIM) presents new Iluvien diabetic macular degeneration data at Association for Research in Vision and Ophthalmology (ARVO) annual meeting. May 4:
Mannkind meets with FDA regarding Afrezza. May 7:
Estimated FDA approval decision date for Merck's ( MRK) hepatitis C drug boceprevir. May 7-10:
Digestive Disease Week research meeting, including data presentation from NPS Pharmaceuticals ( NPSP) and Ironwood Pharmaceuticals ( IRWD). May 9:
Avanir Pharmaceuticals ( AVNR) first-quarter earnings.
Mannkind first-quarter earnings. May 12:
FDA advisory panel convenes to review Biomimetic Therapeutics' ( BMTI) Augment Bone Graft.
Lexicon Pharmaceuticals ( LXRX) analyst/investor meeting. May 18:
American Society of Clinical Oncology (ASCO) releases research abstracts for its annual meeting in June. May 19:
FDA convenes advisory panel to review cardiovascular safety of Abbott Labs' ( ABT) lipid-lowering drug Trilipix. May 23:
FDA approval decision date for Vertex's hepatitis C drug telaprevir.
FDA approval decision date for Johnson & Johnson's ( JNJ) HIV drug rilpivirine. May 25-28:
European League Against Rheumatism (EULAR) annual meeting. May 26:
Johnson & Johnson analyst/investors meeting.
Xoma ( XOMA) shareholder meeting. May 30:
FDA approval decision date for Optimer Pharmaceuticals' ( OPTR) antibiotic fidaxomicin. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.